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Abstract
Glycosylation is the most abundant post-translational polypeptide chain modification in nature. Although carbohydrate
modification of protein antigens from many microbial pathogens constitutes important components of B cell epitopes, the
role in T cell immunity is not completely understood. Here, using ELISPOT and polychromatic flow cytometry, we show that
O-mannosylation of the adhesin, Apa, of Mycobacterium tuberculosis (Mtb) is crucial for its T cell antigenicity in humans and
mice after infection. However, subunit vaccination with both mannosylated and non-mannosylated Apa induced a
comparable magnitude and quality of T cell response and imparted similar levels of protection against Mtb challenge in
mice. Both forms equally improved waning BCG vaccine-induced protection in elderly mice after subunit boosting. Thus, O-
mannosylation of Apa is required for antigenicity but appears to be dispensable for its immunogenicity and protective
efficacy in mice. These results have implications for the development of subunit vaccines using post-translationally modified
proteins such as glycoproteins against infectious diseases like tuberculosis.
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Introduction
Mycobacterium tuberculosis (Mtb), the etiologic agent of tuberculosis
(TB), produces an array of protein antigens (Ags), many of which
are post-translationally modified [1–4], which constitute important
determinants of innate and adaptive immune response. As with
other pathogens, the post-translational protein modifications
influence host interactions. In particular, carbohydrate modifica-
tion of proteins serves as an efficient ligand for innate C-type lectin
receptors (CLRs) present on the antigen presenting cells (APCs).
Members of this receptor family play an important role in immune
response induction, immune evasion, immune regulation and
tolerance [5]. In addition to their role in innate immunity,
carbohydrate modifications of protein Ags contribute to B cell
epitopes, and it has been recently shown that glycopeptides may
constitute a T cell epitope and can induce a strong T cell response
[6]. Consequently, many glycoproteins or glyco-conjugates are
considered Ags of interest in vaccine development. However, little
is known about the role of protein glycosylation in T cell immunity
in TB, and a better definition of immune responses to
glycoproteins may aid in deciphering their role in protection or
pathogenesis of Mtb.
The 45-47-kDa secretory and cell surface alanine-proline-rich
antigen (Apa; Rv1860) is one of the few glycoproteins of Mtb for
which the complete glycosylation pattern has been described [7,8].
The modifications of native Apa (nApa) consist of complex O-
mannosylation of specific threonine residues present at the N- and
C-terminal domains [8,9]. Apa is produced by all members of the
Mtb complex including the vaccine strain, M. bovis bacillus
Calmette Guerin (BCG). The nApa shares significant amino acid
homology with a family of fibronectin attachment proteins found
in other mycobacteria such as M. avium, M. marinum and M. leprae
and is shown to possess fibronectin-binding activity [10]. In Mtb,
mannosylated nApa is a potential adhesin and has a role in host
cell attachment, entry, and immune evasion [11,12].
The nApa is an immunodominant Ag and has been found to be
strongly recognized by serum antibodies (Abs) of active TB
patients [13], and the Ab reactivity was mainly directed against
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mannose residues. The Ag-specific T cell recognition of nApa also
requires mannosylation. These mannose residues are absent in the
recombinant form of Apa (rApa) expressed in E. coli, and the rApa
is poorly recognized by T cells of BCG inoculated guinea pigs
[14,15]. We and others have identified Apa as a possible vaccine
candidate against TB [16–18], but the role of glycosylation in
inducing protective T cell immunity had not been studied.
Here, we investigated the effect of Apa mannosylation on the T
cell antigenicity after mycobacterial infections and the immuno-
genicity and protective efficacy following protein vaccination.
Antigenicity is the ability of the molecule to react with a preformed
Ab or T cell receptor (TCR) while immunogenicity is the ability to
elicit a cell-mediated or humoral immune response [19], which
may or may not impart protection against a pathogen. Our results
demonstrate that the mannosylation of Apa is critical for its T cell
antigenicity in humans and mice after mycobacterial infections
and provide evidence that a synthetic Apa glycopeptide constitutes
a T cell Ag. We show that glycosylation of Apa is expendable for T
cell immunogenicity and protective efficacy when used either as a
subunit vaccine or as a BCG-booster vaccine against Mtb infection
in BALB/c mice. Our data suggest that comparable immunoge-
nicity and protective efficacy of mannosylated and nonmannosy-
lated Apa forms may not be due to the inability of nApa to induce
glycopeptide-specific T cells, as generation of nApa-specific
hybridomas following subunit vaccination of mice identified a T
cell clone specifically reactive to the N-terminal glycopeptide of
nApa. Importantly, our data suggest that Apa may be considered a
possible component of future vaccines against TB to boost waning
BCG immunity, regardless of glycosylation.
Results
Apa Glycosylation and Responses of Human PBMCs
We first determined the role of Apa mannosylation in T cell
recognition and recall of cytokine responses in healthy, BCG
vaccinated (BCG+) and BCG unvaccinated (BCG2) adults. The
peripheral blood mononuclear cells (PBMCs) from 17/24 (70.8%)
BCG+ individuals produced more than 50 IFN-c spot forming
units (SFU)/106 cells (a positive response) after in vitro stimulation
with purified nApa, as compared to those from only 3/24 (12.5%)
individuals after stimulation with rApa (Figure 1A). Among BCG+
individuals, an IFN-c response was predominantly observed in
individuals with positive skin test reactivity to Mtb purified protein
derivatives (PPD+), with 15/16 (93.7%) individuals showing nApa-
specific positive response. Only 2/8 (25%) BCG+ individuals
without PPD reactivity (PPD2) and 1/22 (4.5%) controls, i.e.
BCG2PPD2 individuals, responded positively to nApa. This
dominant nApa-specific T cell response was dose dependent, as
demonstrated by the increased frequency of IFN-c SFU when
PBMCs of 5 healthy PPD+ (including 3 confirmed Mtb-exposed)
individuals were stimulated with varying amounts of nApa, in
contrast to different doses of rApa (Figure S1A). Overall, these
results demonstrate that nApa is recognized preferentially over
rApa in these individuals.
Next, we characterized the Ag-specific IFN-c, TNF-a and IL-2
cytokine responses of 8 randomly selected BCG+PPD+ subjects by
intracellular cytokine staining (ICS) and polychromatic flow
cytometry and determined the percentages of CD4+ and CD8+
T cells expressing one (1+), any combination of two (2+), or all
three (3+) cytokines. Significantly higher frequencies of IFN-c,
TNF-a or IL-2 producing CD4+ T cells were observed in nApa
stimulated PBMCs than those stimulated with rApa (Figure 1B
and 1C) and the response was characterized by higher percentages
(but comparable proportions) of nApa-specific polyfunctional
CD4+ T cells in the responding donors (Figure S1B). In contrast,
the frequency of total cytokine producing CD8+ T cells was not
statistically different after stimulation with the two forms of Apa
(Figure 1C), although 4 donors had more nApa-specific cytokine
producing CD8+ T cells. Collectively, these results suggest that
mannosylation of Apa is important for the Ag-specific T cell recall
responses in these individuals.
The heightened T cell responses seen with mannosylated Ags
are presumably due to efficient uptake through mannose binding
CLRs on the APCs such as dendritic cells (DCs) and higher
efficiency of Ag presentation [20–22]. Therefore, we sought to
determine whether Apa mannosylation influences its uptake by
DCs. We found increased binding/uptake of FITC-labeled nApa
as compared to labeled rApa by the blood monocyte derived
dendritic cells (MoDCs) and by the CD11c+HLA-DR+ myeloid
dendritic cells (mDCs) in the PBMCs of BCG+ and BCG2
individuals (Figure S1C and D). A higher percentage of myeloid
(mDCs) but not plasmacytoid dendritic cells (pDCs) from human
PBMCs expressed CD80 following in vitro stimulation with nApa
than after rApa (Figure 1D and 1E), suggesting increased
activation of mDCs by nApa. It is known that mannose binding
CLRs such as DC-specific intracellular adhesion molecule-3
grabbing nonintegrin (DC-SIGN) and mannose receptor (MR)
are highly expressed on mDCs but are absent on pDCs, and play
an important role in the uptake and presentation of mannosylated
Ags [23]. Corroborating these observations, we found that nApa
but not rApa binds to recombinant human MR, DC-SIGN and
DC-SIGNR using an in vitro CLR adhesion assay (Figure 1F).
To determine whether Ag presentation of nApa to specific T
cells requires intracellular processing, APCs were fixed with
glutaraldehyde before or after Ag pulsing. The MoDCs generated
from the blood monocytes of three nApa-responding individuals
(BCG+PPD+) were used as APCs, while T cells were purified from
the PBMCs of respective individuals. The IFN-c ELISPOT was
used to investigate Ag presentation and activation of T cells after
co-culture. Glutaraldehyde fixation of APCs before addition of
nApa abrogated IFN-c response (Figure S1E), whereas fixation of
APCs after pulsing with nApa did not prevent IFN-c production,
Author Summary
Mycobacterium tuberculosis (Mtb) is the most devastating
bacterial pathogen of all time that kills approximately 1.4
million people each year. Mtb modifies several of its
proteins with sugar residues that influence many biolog-
ical events. However, the significance of such sugar
decorations and resulting carbohydrate and glycopeptide
epitopes in shaping the T cell response during infection or
after vaccination is insufficiently understood. Here, we
show that the carbohydrate modifications of the Mtb Apa
protein strikingly influence the magnitude of specific T cell
responses in humans and mice after infection, but have
only minor effect on the polyfunctionality and quality of T
cell responses. The glycosylation of Apa was, however,
expendable for T cell immunogenicity and protective
efficacy when used either as a subunit vaccine or as a BCG-
booster vaccine in dimethyl-dioctadecyl ammonium bro-
mide (DDA)-monophosphoryl lipid A (MPL) adjuvant
against virulent Mtb infection in mice. Our results suggest
that the carbohydrate modification of microbial protein
antigens may not always be critical for protection as our
unmodified recombinant protein was sufficient for subunit
vaccination. Together, our data underline the need to
understand the role of heightened Apa glycoprotein-
specific T cell responses in infection processes.
Glycosylation of Mtb Apa and T Cell Immunity
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although the response (SFU) was lower than pulsing of Ag alone
without fixation. These results indicate a requirement for
intracellular processing of nApa for presentation to T cells. In
contrast, fixation of APCs before addition of the superantigen,
staphylococcal enterotoxin B (SEB), did not prevent the IFN-c
response of T cells. Therefore, the lack of nApa-specific IFN-c
secretion by specific T cells, if fixation of APCs preceded Ag
pulsing, is consistent with the presentation of cognate Ag (versus
superantigen) [24,25].
Next, to determine whether increased binding/uptake and
activation of mDCs by nApa influences T cell reactivity and
epitope recognition, we screened 32 sequential nonmodified
synthetic overlapping peptides of Apa with PBMCs of BCG+PPD+
individuals who recognized both forms of Apa and those who
recognized nApa over rApa. Several peptides induced positive
IFN-c responses in PBMCs from individuals who recognized both
forms of Apa (Figure S1F), whereas no peptide induced .20 IFN-
c SFU/106 PBMCs from individuals who recognized only nApa.
These results suggest that mannosylation of Apa does not induce
alternate Ag processing in APCs to produce unique peptide
epitopes, but rather carbohydrate contributes to T cell epitopes
and recognition of such mannosylated epitopes (for example
glycopeptides) is probably responsible for elevated T cell responses
to nApa in these individuals.
nApa Is More Antigenic Than rApa in BCG or Mtb Infected
Mice
To determine whether Apa mannosylation is required for T cell
antigenicity in animal models, BALB/c mice were infected with
Mtb intranasally (i.n.) or with M. bovis BCG subcutaneously (s.c.).
At different time points after infection, lung, spleen and draining
inguinal lymph node (ILN) cells were isolated and stimulated with
nApa or rApa. The frequency of IFN-c, TNF-a and IL-2
producing CD4+ T cells after nApa stimulation of lung and spleen
cells from BCG-administered mice was comparable (IFN-c, IL-2)
to 2-fold (TNF-a) more than that induced by nAg85B stimulation,
whereas stimulation by rApa induced only a marginal increase in
Figure 1. Human PBMC responses to nApa and rApa. (A–E) PBMCs from healthy donors were stimulated in vitro with no Ag, nApa, rApa or
WCL, and the T cell or DC responses were investigated. (A) IFN-c SFU/106 PBMCs of BCG vaccinated (BCG+) and unvaccinated (BCG2) donors with
(PPD+) or without (PPD2) reactivity to purified protein derivative, following stimulation with nApa or rApa. The median IFN-c SFU/106 PBMCs in no Ag
stimulated wells (media only) were 7.5 (range 0–46.5) and 4.0 (range 0–37.5) for BCG+ and BCG2 donors, respectively. (B) The percentages (%) of TNF-
a and IFN-c (top) or IL-2 (bottom) producing cells among CD4+ T cells from 1 representative BCG+ PPD+ donor are shown, and (C) the frequency (%) of
total cytokine producing cells among CD4+ (top) and CD8+ (bottom) T cells from 8 BCG+ PPD+ donors are plotted. (D) The % of CD123+ pDCs and
CD11c+ mDCs expressing activation markers CD80 and HLA-DR in BCG+ PPD+ donor are shown (lower panel). The gating strategy for the two DC
subsets is also depicted (upper panel). Similar results were obtained in BCG+ PPD2 donor. (E) Summary of pDCs and mDCs activation from 3 BCG+
donors regardless of PPD status. (F) Binding of nApa or rApa to recombinant human MR, DC-SIGN and DC-SIGNR in vitro. Data are representative of 2
independent experiments. Horizontal bars (A, C) and error bars (E, F) indicate the medians and means 6 S.D., respectively. *Significant using 2-tailed
Wilcoxon matched-pairs signed rank test (A and C) and by ANOVA (E, F).
doi:10.1371/journal.ppat.1003705.g001
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the frequency of cytokine secreting CD4+ T cells as compared to
controls (Figure 2A and S2A). Similar results were also obtained
using ILN cells (data not shown).
The time kinetics of CD4+ T cell response confirmed the
presence of significantly higher frequency of nApa-specific total
cytokine secreting cells in the lung (p = 0.0002) and spleen
(p = 0.0021) as compared to those specific for rApa (Figure 2B)
and revealed that the Apa responses peaked at 32–52 weeks (wks)
after BCG administration, with a similar expansion and contrac-
tion trend for the nApa- and rApa-specific T cells. During the
expansion phase, 3.9- and 8.6-fold more nApa-specific total
cytokine secreting CD4+ T cells were observed at 12 wks in the
lung and spleen, while at the peak (52 wks) the increase was 7.7-
and 2.7-fold more in the lung and spleen, respectively. At
individual cytokine levels, however, the difference between nApa-
and rApa-specific cytokine producing CD4+ T cell frequency was
more pronounced for IFN-c and TNF-a (Figure S2B). These
results suggest that mannosylation of Apa strongly influences the
magnitude of Apa-specific CD4+ T cell responses in BCG
administered mice and indicates that the CD4+ T cells of these
mice predominantly recognize major histocompatibility complex-
II (MHC-II) restricted epitopes present in nApa only. On the
contrary, the frequency of nApa- and rApa-specific total cytokine
secreting CD8+ T cells was not significantly different at the time
points evaluated, except at the 32 wk time point in the lung
(Figure 2B). This difference in the lung was mainly due to the
presence of a higher frequency of nApa-specific IFN-c producing
CD8+ T cells (Figure S2C). These results indicate that both forms
of Apa possess MHC-I restricted epitopes recognized by the CD8+
T cells of BCG administered mice.
Next, we compared the cytokine expression profiles of nApa-
and rApa-specific CD4+ or CD8+ T cells. The lung CD8+ T cell
response was dominated almost exclusively by 1+ cytokine (IFN-c)
producing cells (Figure 2C, histograms). In contrast, about 38%
Figure 2. T cell responses to nApa and rApa in BCG infected mice. (A–E) Mice were infected s.c. with 16106 CFU BCG. At different time points
after infection, as indicated, mice were euthanized (n = 4/time point) and their spleen or lung cells (pools) were stimulated in vitro with no Ag, nApa,
rApa, nAg85B or WCL. (A) The percentages (%) of TNF-a and IFN-c (top) or IL-2 (bottom) producing cells among lung CD4+ T cells from 1
representative experiment at the 52 wk time point are shown, and (B) the frequency (%) of nApa- or rApa-specific total cytokine producing cells
among CD4+ and CD8+ T cells from the spleen and lung at 7 different time points encompassing entire life span are plotted. (C–D) nApa or rApa-
specific cytokine co-expression profiles in the lung and spleen were determined, and (C) the proportions of single (1+), double (2+), or triple (3+)
cytokine producing T cell subsets constituting total cytokine positive (+) CD4+ or CD8+ T cells at the peak of response are plotted as % of CD4+ T cells
(top; at 52 wk) or CD8+ T cells (bottom; at 32 wk), respectively. The pie charts present the mean frequencies of 1+, 2+ and 3+ cytokine producers. (D)
The percentages of 7 possible combinations of cytokine secreting subsets in the lung are also shown. Data at 12, 32, 52 and 72 wks (in B–D) are
means 6 s.e.m. of 3–4 independent mice experiments, while data (means) at 3, 6 and 104 wks are from one experiment evaluated in duplicate. Total
as well as individual cytokine subset responses are compared. (E) nApa- or rApa-specific IFN-c, IL-17 or IL-4 SFU/106 lung or spleen cells at 12, 32 and
72 wks. Data are means 6 s.e.m. of 2 independent mice experiments evaluated in triplicate. The pie charts present the mean IFN-c, IL-17 and IL-4
SFU/106 cells at 32 wk. *Significant using 1-way ANOVA followed by Bonferroni’s multiple comparison test (B–E).
doi:10.1371/journal.ppat.1003705.g002
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and 50% of the nApa-specific cytokine secreting CD4+ T cells
produced more than 1 cytokine at the peak (52 wk) time point in
the lung and spleen, respectively, and a significantly higher
frequency of 2+ and 1+ cytokine producing CD4+ T cells was
observed after stimulation with nApa than rApa in the lung
(Figure 2C, histograms). When the Ag-specific cytokine producing
lung CD4+ T cells were categorized into 7 distinct subpopulations
based on cytokine expression profiles, IFN-c and TNF-a co-
producing cells dominated nApa-specific 2+ cytokine producing
cells (Figure 2D), while IFN-c or TNF alone producing cells were
predominantly present among nApa-specific 1+ cytokine produc-
ers. Despite differences in the magnitudes, the proportions of
nApa- and rApa-specific cytokine producing 3+, 2+ and 1+
cytokine producing CD4+ or CD8+ T cells was not significantly
different in both organs at the peak time point (Figure 2C, pie
charts).
The proportions of nApa- and rApa-specific IFN-c, IL-4 and
IL-17 SFU in cultured ELISPOT assay were also not significantly
different when compared at 3 time points; however, statistically
higher frequency of IFN-c or IL-17 SFU was present in the lung
and spleen cell cultures after nApa stimulation (Figure 2E). These
results collectively suggest that Apa mannosylation may have only
minor effect on the polyfunctionality and ratios of specific
subpopulations of Apa-specific T cells in BCG inoculated mice.
Similar dynamics were observed in Mtb Erdman infected mice
(Figure S2D–F).
Artificial Glycosylation of rApa C-terminus and T Cell
Antigenicity
Thirty-two non-modified, synthetic overlapping peptides of Apa
were screened for their capacity to induce IFN-c response in mice
at 12 and 32 wks post BCG infection. Only peptide p271-288
induced a positive response which only occurred 32 wks after
infection (Figure 3A). These analyses support the indication that
heightened T cell responses to nApa are mainly due to
glycosylation. We synthesized rApa C-terminal peptide (residues
281–325; 45-mer) with di-mannosyl-threonine residue at position
316 (Fig. S3A), akin to that found in nApa, to confirm the role of
Apa glycosylation in T cell antigenicity.
A higher frequency of IFN-c SFU was observed in the spleen
and lung cell cultures of BCG and Mtb infected mice after
stimulation with the synthetic glycopeptide as compared to
stimulation with the non-glycosylated control peptide (Figure 3B),
confirming the role of Apa glycosylation in T cell antigenicity. A
higher frequency of cytokine producing CD4+ T cells, but not
CD8+ T cells, was found in the splenocytes of BCG mice after in
vitro stimulation with glycopeptide compared to stimulation with
control peptide (Figure 3C), suggesting that the carbohydrate
modification of nApa C-terminus may constitute a CD4+ T cell
epitope. The T cell epitope prediction analyses also indicated
probable binding of a 15-mer encompassing Thr316 to MHC-II
molecules (Figure S3B).
To determine whether T cells recognize carbohydrate (di-
mannose) in the absence of the proper peptide context, we
synthesized rApa C-terminal 45-mer peptide with di-mannosyl-
threonine residue at its N-terminus (at an unnatural position)
linked by the additional glycine residues (Figure S3C). We termed
this Apa 45-mer with additional four N-terminal residues as a 49-
mer glycopeptide (i.e., Apa non-glycopeptide residues 281–325
with Gly-Thr(di-man)-Gly-Gly extension). Significant cytokine
response was observed in ELISPOT when the lung, spleen or
ILN cells from the BCG mice were stimulated with the synthetic
45-mer glycopeptide with a di-mannosyl residue at its natural
position (Thr316). On the contrary, no positive cytokine response
was found after in vitro stimulation with the 49-mer glycopeptide,
49-mer nonglycopeptide (control) or the free di-mannose alone
(Figure S3D). These results suggest that the carbohydrate (di-
mannose) attached to the proper peptide backbone is likely
required for the recognition of nApa C-terminal glycopeptide by
specific T cells from BCG mice. Further characterization of MHC
bound glycopeptide interactions with the TCR and the orientation
of carbohydrate residues can be accomplished through crystallog-
raphy studies.
Both nApa and rApa Are Immunogenic Following
Subunit Vaccination of Mice
To determine whether mannosylation of Apa also influences its
ability to induce a protective immune response, mice were
vaccinated s.c. with 3 doses of nApa or rApa (1 mg/dose) in the
presence of dimethyl-dioctadecyl ammonium bromide (DDA) and
monophosphoryl lipid A (MPL) adjuvants at 4 wk intervals, and
the T cell responses were investigated 1 wk after the last dose.
Stimulation of splenocytes or ILN cells of vaccinated mice with
either nApa or rApa, resulted in a comparable frequency of
individual cytokine producing CD4+ T cells, regardless of which
form of the Ag was used for vaccination. This Apa-specific T cell
response was characterized by more TNF-a and IL-2 than IFN-c
producing cells in an ICS assay (Figure 4A, 4B and S4A). The
frequency of Ag-specific total cytokine producing CD4+ and CD8+
T cells induced in the spleen and lung by either Apa vaccine was
also comparable (Figure 4C).
When the cytokine expression profiles of CD4+ T cells from the
spleen and lung were evaluated in the vaccinated groups, IL-2 and
TNF-a co-producing cells dominated 2+ cytokine producing cells,
while TNF-a or IL-2 single-producers were predominantly present
among 1+ cytokine producing cells (Figure 4A). In contrast, the
cytokine expression profiles of CD8+ T cells in the spleen and lung
were dominated by TNF-a or IFN-c secreting 1+ cytokine
producers, respectively. Higher proportions of total cytokine
producing splenic CD4+ T cells of rApa vaccinated mice consisted
of polyfunctional T cells than those of nApa vaccinated mice
(Figure 4C). Otherwise, we found no significant difference in the
quality of nApa- and rApa-specific response, when the proportions
of 3+, 2+ and 1+ cytokine producing CD4+ and CD8+ T cells were
determined in the two vaccinated groups. Significantly more
immunogen-specific IL-17 and IFN-c SFU were observed in the
spleens of rApa vaccinated as compared to nApa vaccinated mice
in cultured ELISPOT assay (Figure 4D, histograms). However, the
proportions of specific IFN-c, IL-17 and IL-4 SFU constituting the
total ELISPOT response were not significantly different in nApa
or rApa vaccinated mice (Figure 4D, pie charts).
Synthetic peptide screening in nApa and rApa vaccinated mice
revealed that T cell cytokine responses were predominantly
directed toward non-glycosylated p271-288 and p231-250 pep-
tides (Figure S4B), regardless of the immunogen used, indicating
that Apa mannosylation does not induce alternate Ag processing
in vivo when administered in DDA-MPL. Next, we evaluated the
lung and splenic T cell responses of C-terminal 45-mer
glycopeptide (Gp-281-325) in nApa vaccinated mice. Compara-
ble cytokine SFU after in vitro stimulation with 45-mer glycopep-
tide and its non-glycosylated control were found, regardless of
dose of nApa (1 or 10 mg) used for vaccination (Figure 4E), and
the p271-288-specific response was significantly more than that
induced by Gp-281-325, collectively suggesting that the differ-
ences observed between nApa and rApa induced T-cell responses
may be partially overcome by co-administration of appropriate
adjuvants.
Glycosylation of Mtb Apa and T Cell Immunity
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Generation of nApa-Specific Hybridomas Identify
N-terminal Glycopeptide-Reactive T Cell Clone
Since nApa is also glycosylated with complex mannose modifi-
cations at its N-terminus (Figure S3B), the presence of N-terminal
glycopeptide(s)-specific T cells in our nApa vaccinated mice samples
remained a possibility. Our preliminary attempt to synthesize and
evaluate N-terminal glycopeptide (39-mer) was unsuccessful, and
whether nApa glycopeptide-specific T cells are generated following
subunit vaccination was not clear. Therefore, to identify nApa-
specific T cell clones we employed a specialized protocol of T-cell
hybridoma generation, using a single dose nApa vaccination of
BALB/c mice in Freund’s incomplete adjuvant (FIA). Individual T
cell clones responding to nApa were purified by serial dilutions and
tested for reactivity to nApa or rApa using an IL-2 capture ELISA
after co-culture with APCs (i.e., syngeneic bone marrow derived
dendritic cells) pulsed with Ag. Of the total 17 Apa-reactive
hybridoma clones developed, 7 clones recognized both nApa and
rApa while 10 clones recognized only nApa and not rApa (data not
shown). Three of the 7 clones that recognized both nApa and rApa
responded to a specific synthetic, nonmodified 15-mer peptide (two
reactive to peptides spanning p271-288, and one to peptide p70-84,
data not shown), while none of the 10 nApa reactive clones
recognized any of the synthetic, overlapping, nonmodified peptides.
Of the 10 clones only reacting to nApa, one clone, 4C3, reacted
with a glycopeptide fraction of trypsin digested nApa fractionated
by a reversed phase-HPLC column chromatography. Clone 4C3
produced significant amount of IL-2 when cultured with APCs
pulsed with the whole digest of nApa but not with the digest of rApa
(Figure 5A), indicating that the Ag presentation of nApa to 4C3 T
cell clone was not inhibited by trypsin digestion. The RP-HPLC
fractions consisting of the N-terminal 106 amino acid glycopeptide
(residues p40-145) of nApa only demonstrated reactivity in IL-2
assay (Figure 5B, Figure S5A and S5B). Glycosylation of the N-
terminus of nApa from Mtb likely explains specific recognition of the
4C3 clone to the nApa peptide. The lack of biological activity of T
cell clone 4C3 when presented with rApa or synthetic nonglyco-
sylated peptides collectively suggest that N-terminal glycopeptide-
specific T cells are generated after nApa subunit vaccination.
Further confirmation of these results will require identification of the
precise epitope and synthesis of the N-terminal glycopeptide.
Figure 3. T cell reactivity to in vitro-mannosylated rApa C-terminal. (A) Pooled splenocytes from BCG infected mice (n = 4) were stimulated in
vitro with nApa, rApa or 32 individual non-glycosylated synthetic Apa peptides in ELISPOT assay. IFN-c SFU/106 cells at 12 and 32 wk time points are
shown. (B–C) Synthetic C-terminal glycopeptide (Gp281-325)- or control non-glycopeptide (NGp281-325)-specific T cell response (indicated inside
dotted box) in mice. Stimulation with proteins (nApa or rApa) or non-glycopeptides (p271-288 or p301-320) was also included as controls. (B) Ag- or
peptide-specific IFN-c, IL-17 or IL-4 SFU/106 pooled lung or spleen cells of BCG or Mtb infected mice at 32 and 26 wks, respectively. (C) The
proportions of peptide-specific 1+, 2+ and 3+ cytokine producing T cell subsets constituting total cytokine positive (+) CD4+ T cells in the spleen of
BCG infected mice at 32 wks, expressed as % of CD4+ T cells. Data in A–C are means 6 s.e.m. *Significant using 1-way ANOVA followed by
Bonferroni’s test.
doi:10.1371/journal.ppat.1003705.g003
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nApa or rApa Vaccination Imparts Comparable
Protection against Mtb Challenge
We investigated the protective efficacy of two Apa forms using
DDA-MPL, a known Th1 adjuvant. BALB/c mice were
vaccinated s.c. with nApa or rApa 3-times at 4 wk intervals using
two different concentrations (1 or 10 mg), in DDA-MPL adjuvant
and challenged with Mtb 4 wks after the last dose to assess their
protective potential. Mice vaccinated with nAg85B, a known
protective Ag, were included for comparison. Mice immunized
once with live BCG at the start of vaccination were used as positive
controls, while negative controls received adjuvant alone (3-times)
or were left untreated (naı̈ve). Both forms of Apa imparted
significant protection compared to naı̈ve and adjuvant control
groups at 2 different doses used (Figure 6A), and the bacterial
burden among the Apa vaccinated groups was not significantly
different. Vaccination with nAg85B also induced protection, but
only nAg85B-10 mg was statistically different from the negative
control groups at the level of lung and spleen. However, the degree
of protection afforded by BCG vaccination was greater than any of
the subunit vaccinated groups. Vaccination with either nApa or
rApa induces comparable levels of protection in our model and
suggests that glycosylation of Apa is not critical for protection.
Apa Vaccination and Ability to Recall T and B Cell
Responses after Challenge
To ascertain whether comparable protective efficacy offered by
nApa and rApa vaccination in mice correlated with an equal
ability to recall cellular and humoral immune responses after Mtb
challenge, T cell responses and serum Ab titers were measured
before Mtb challenge (at 4 wks after last vaccination) and 6 wks
post challenge. All Apa vaccinated groups presented with an equal
vaccine immunogen-specific CD4+ T cell recall response in the
lungs after challenge, characterized by a significantly higher
frequency of total cytokine producing CD4+ T cells in the post-
challenge versus pre-challenge group (Figure 6B). Significant recall
from spleen derived T cells was only observed in rApa-1 mg group.
No significant differences were observed when the immunogen-
specific lung or spleen CD8+ T cell responses were compared
between vaccine immunogens; however, the CD8+ T cell
responses of all vaccinated groups were higher than those of
control groups in the lungs. Both nApa and rApa were recognized
equally well when used for stimulation of lung and spleen cells of
vaccinated and challenged groups (Figure S6A). Comparable
patterns of cytokine co-expression profiles were found when T cell
responses of respective Apa vaccinated groups were compared
Figure 4. T cell responses in nApa or rApa vaccinated mice. (A–D) Mice were vaccinated with nApa or rApa in DDA-MPL adjuvant or with
adjuvant alone (controls), and their spleen or lung cells were stimulated in vitro with no Ag, nApa or rApa 1 wk after last vaccination. (A) The
percentages (%) of TNF-a and IFN-c (top) or IL-2 (bottom) producing cells among splenic CD4 T cells of 1 representative mouse from nApa or rApa
vaccinated group are shown, and (B) the frequency (%) of nApa- or rApa-specific individual cytokine producing cells among splenic CD4+ T cells from
4 mice/vaccinated group is plotted ( means 6 s.e.m.). (C) The frequency (%) of nApa- or rApa-specific total cytokine producing cells among CD4+
(top) and CD8+ (bottom) T cells from the spleen (means 6 s.e.m., n = 4 mice/group) and lung (pools) of nApa or rApa vaccinated (vac) mice. The
corresponding pie charts present the mean frequencies of 1+, 2+ and 3+ cytokine producers. (D) The frequency of nApa- or rApa-specific IFN-c, IL-17
or IL-4 SFU/106 spleen or lung cells of vaccinated (vac) and control mice. The corresponding pie charts present the mean cytokine frequencies. Data
are means 6 s.e.m. of 3–4 wells using pooled cells. The responses of 2 Apa vaccinated groups were compared. *Significant by 1-way ANOVA followed
by Bonferroni’s test comparing respective immunogen-specific responses. (E) Synthetic Gp281-325- or NGp281-325-specific cytokine response of
nApa vaccinated mice 4 wks post-vaccination. Stimulation with p231-250, p271-288 or p301-320 was evaluated for comparison.
doi:10.1371/journal.ppat.1003705.g004
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before and after challenge (Figure 6B); characterized by immuno-
gen-specific TNF-a and IL-2 producing 2+ and 1+ CD4+ T cells in
the spleen and IFN-c producing 1+ CD4+ and CD8+ T cells in the
lungs. On the contrary, splenic CD4+ T cells responses of the
challenged naı̈ve controls were characterized by nApa-specific
IFN-c and TNF-a producing 1+ and 2+ CD4+ T cells only.
The cultured ELISPOT assay revealed that the frequency of
immunogen-specific total IFN-c, IL-17 and IL-4 SFU in the lung
was significantly lower in vaccinated-challenged groups compared
to respective vaccinated group pre-challenge (Figure 6C). These
results suggest possible decrease in in vitro proliferation of
immunogen-specific lung T cells in ELISPOT cultures after
recent in vivo recall or regulatory responses suppressing cytokine
release following Mtb challenge. Proof for any of these explana-
tions will require further in-depth investigation. All Apa vaccinated
groups produced comparable amounts of immunogen-specific
serum IgG1 Abs before and after challenge (Figure 6D), and these
Abs recognized nApa and rApa equally well (Figure S6B).
However, rApa vaccination induced significantly higher amounts
of IgG2a and IgG2b Abs than nApa vaccination, except at 10 mg
dose post-challenge.
Of importance, when pathogen-specific immune responses were
investigated in the lung and spleen of vaccinated and control
groups of mice in vitro, higher frequency of Mtb short term culture
filtrate (STCF)-specific total cytokine producing CD4+ and CD8+
T cells was observed in naı̈ve and adjuvant only mice as compared
to vaccinated mice post-challenge (Figure 7A), with a significant
difference at the level of lung. As expected, STCF-specific
responses of unvaccinated-challenged mice were dominated by
IFN-c and TNF-a 1+ and 2+ CD4+ T cells and IFN-c 1+ CD8+ T
cells. Furthermore, when STCF-specific IFN-c, IL-17 and IL-4
SFU were compared among challenged groups, responses of
unvaccinated mice were found to be highly skewed toward IFN-c
(87–96% of total response), with significantly more SFU compared
to all vaccinated groups (Figure 7B).
Apa Glycosylation and Boosting BCG-Induced Immunity
Considering the fact that most individuals in the world have
been vaccinated with BCG and new TB vaccines have to be
considered in the context of prior BCG vaccination, development
of strategies aimed at boosting and improving the protective
immunity induced by BCG is considered to be one of the rational
approaches to develop an effective vaccination regimen against
TB. Since BCG induced protection wanes significantly by 18
months in mice (unpublished data), we investigated the booster
effect of 2 doses of nApa or rApa administered 3 wks apart in
DDA-MPL at 16 months after BCG vaccination. Both forms of
Apa significantly boosted T cell responses compared to boosting
with saline, and a significantly higher frequency of T cells from the
Apa-boosted groups recognized nApa over rApa after in vitro
stimulation (Figure 8A and B). Nonetheless, comparable nApa-
specific responses were found in both Apa-boosted groups, except
for splenic IFN-c SFU. Of importance, boosting with either form
of Apa, but not with saline, significantly reduced Mtb CFU in the
lung and spleen of BCG mice compared to age-matched controls
(Figure 8C). BCG mice boosted with nApa or rApa showed about
2.0-log reduction in bacterial counts in the lungs as compared to
age-matched naı̈ve mice, while 1.7-log to 2.0-log reduction was
found in the spleens of nApa- and rApa-boosted mice, respectively.
This protection is characterized by a significantly lower frequency
of ESAT-6+CFP-10-specific total as well as CD4+ T cell IFN-c
responses in the spleens of Apa-boosted groups (Figure 8D).
Discussion
Glycosylation generates an enormous variety of modified
protein-derived epitopes. However, the significance of such
modified antigenic epitopes in intracellular bacterial pathogens
in shaping the T cell repertoire and determining the outcome of an
immune response is poorly understood. Here we demonstrate that
mannosylation of Mtb Apa (also known as MPT-32 or ModD) is
crucial for its T cell antigenicity during mycobacterial infections of
humans and mice and provides direct evidence that bacterial
mannopeptides are T cell Ags using a synthetic Apa glycopeptide.
Previously, glycopeptides containing tumor associated carbohy-
drates [26,27], glycopeptides of self-Ags in autoimmune diseases
[28], and artificially glycosylated peptides of model Ags [6] have
been shown to be recognized by T cells. In antigenic glycopep-
tides, the peptide backbone usually provides the binding motif that
interacts with the MHC molecule, while the glycan provides an
important part of the structure (epitope) that is recognized by the
T cell receptor [29]. Conversely, pure carbohydrates are usually
incapable of MHC binding and T cell stimulation, and due to their
haptenic nature requires a carrier. The exception to this immuno-
logic paradigm is zwitterionic polysaccharides which are presented
Figure 5. Characterization of nApa-specific T cell hybridoma
clone (4C3). (A–B) The T cell hybridoma 4C3 was generated using
draining LN cells of nApa-FIA vaccinated mice. The Ag and epitope
specificity of 4C3 T cell clone was determined using IL-2 assay. (A) The
4C3 T cells (56104 cells/well) were cultured with APCs pulsed with
indicated amounts of nApa, rApa or whole trypsin digests using T cell to
APC ratio of 1:1 for 24 h and culture supernatants were evaluated using
IL-2 ELISA. (B) Identification of peptide/epitope specific for 4C3 T cell
clone. The nApa was digested with trypsin and the peptide fragments
were resolved by RP-HPLC, total 25 fractions were collected. Fractions
7–25 containing nApa peptides were used to screen the biological
activity of 4C3 clone in IL-2 assay. The whole digest of nApa and
fractions 19, 21, and 22 containing single N-terminal glycopeptide
(residues p40-145) produced a positive IL-2 response when used for Ag
pulsing of APCs. The fraction 19 is characterized by LC-MS (Figure S5B).
The data (A and B) are means (O.D. 405 nm) of culture supernatant
evaluations from two separate cultures in IL-2 ELISA. The experiment
was repeated with similar results.
doi:10.1371/journal.ppat.1003705.g005
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in an MHC class-II restricted manner [30]. Because complex
carbohydrates are not removed during processing by DCs, it
remains possible that mannosylated peptide epitopes within nApa
are recognized in vitro by T cells primed in infected mice and
humans [31]. Our synthetic peptide screenings suggest that the
recognition of carbohydrate containing epitopes (i.e., glycopeptides)
rather than increased Ag uptake, mDCs activation or alternate Ag
processing leading to enhanced recognition of other peptide
epitopes is the major determining factor for heightened T cell
responses to nApa during infection. Mapping of the precise
mannosylated epitopes will further help to identify whether
mannose binds to the MHC groove along with peptide backbone
or interacts strictly with TCR and will provide direct insight into the
role of mannosylation in Ag presentation of Apa to T cells.
Unexpectedly, vaccination of mice with nApa or rApa induced
comparable CD4+ or CD8+ T cell frequency, regardless of the
form of Apa used for in vitro stimulation. Nonetheless, these data
together with post-challenge recall responses revealed that the
paucity of anti-rApa T cell responses after primary infection,
especially CD4+ T cell responses, is not due to an intrinsic inability
of rApa to induce these responses. However, why nApa is
recognized highly discriminately by T cells during infection but
not after subunit vaccination remains to be answered. Specula-
tively, mannosylated epitope(s) of nApa might be effectively
generated in phagosomes during intracellular growth of BCG or
Mtb in vivo, but the relative dominance of mannose bearing
epitopes versus peptide epitopes may change during processing of
nApa in the presence of DDA-MPL in the endo-lysosomes of
APCs in vivo following subunit vaccination. It is known that
transport to different types of compartments in APC can lead to
differential processing and generation of different epitopes within
the same protein [32] and that different T cell epitopes in the same
protein have been found to be recognized during infection and after
subunit vaccination [32]. In our protocol, the majority of specific T
cells generated after nApa-DDA-MPL vaccination might have been
directed against the dominant peptide epitopes (such as p271-288
Figure 6. Protective potential of Apa against Mtb challenge and recall of T and B cell responses. (A) Protective efficacy of nApa or rApa
vaccinated mice using 1 or 10 mg/dose in DDA-MPL against Mtb challenge. Twelve wks after first vaccine injection, mice were challenged with virulent
Mtb Erdman. The differences in bacterial load between vaccinated and nonvaccinated control groups 6 wks after challenge are shown. Data are using
5–10 mice per group. (B–C) T cell responses of Apa vaccinated and control mice pre- and post-challenge. Respective immunogen (i.e. Apa form used
for vaccination)-specific responses in Apa vaccinated (vac) groups while nApa-specific responses in control groups are shown. (B) The proportions of
1+, 2+, or 3+ cytokine producers (of IFN-c, TNF-a and IL-2) constituting Apa-specific total cytokine positive (+) CD4+ or CD8+ T cells are plotted as % of
CD4+ T cells (top) or CD8+ (bottom) T cells in the lungs and spleen of Apa vaccinated and control mice. Data are means 6 s.e.m. of 4 mice/group. (C)
The frequency of Apa-specific IFN-c, IL-17 or IL-4 SFU/106 pooled spleen or lung cells of vaccinated and control mice. Data are means 6 s.e.m. of
triplicate cultures. (D) Immunogen-specific IgG1, IgG2a and IgG2b antibody titers in the sera of Apa vaccinated mice. Data are means 6 s.e.m. of 4
mice/group. Data in A, B and D are representative of 2 independent experiments. *Significant by Kruskal-Wallis followed by Dunn’s test comparing
vaccinated group with naı̈ve and adjuvant controls in protection experiment (A), by 1-way ANOVA followed by Bonferroni’s test comparing pre- and
post-challenge responses of respective vaccinated groups (B and C) or comparing indicated groups (D).
doi:10.1371/journal.ppat.1003705.g006
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and p231-250) and the frequency of glycopeptide-specific T cells, if
at all generated, might have been diminished in nApa stimulated in
vitro cultures. The carbohydrate or glycopeptide epitope-specific T
cells induced by glycoprotein vaccination have been reported to be
scarce and highly sensitive to in vitro culture conditions [6,33]. The
requirement of specialized protocols for their expansion [33]
including generation of T cell hybridomas has been suggested.
Generation of nApa-specific T cell hybridomas following subunit
vaccination of mice using FIA identified a T cell clone (4C3)
specifically responding to the glycosylated N-terminal peptide of
nApa. The dominant nature of peptide epitope p271-288 was also
confirmed, because two hybridomas (3F7 and 2D10) that recog-
nized both nApa and rApa strongly recognized synthetic peptides
spanning p271-288 in IL-2 assay (data not shown). Therefore, the
comparable immunogenicity of nApa and rApa following subunit
vaccination may not be due to the inability of nApa to induce
glycopeptide-specific T cells.
Of paramount importance, both nApa and rApa offered
comparable protection against virulent Mtb challenge in mice,
regardless of whether the 1 or 10 mg/dose was used for vaccination.
Despite higher in vitro immunogen-specific cytokine SFU induced in
the lungs by 1 mg than 10 mg/dose vaccination and the subtle
differences in the quality of serum Ab response induced by the two
forms of Apa vaccination prechallenge, comparable protection was
found in all Apa vaccinated groups. Therefore, mannosylation
appears to be dispensable for protective efficacy of Apa in DDA-
MPL adjuvant in our model of progressive TB. It remains to be seen
whether heightened T cell responses can be induced against nApa
than its recombinant counterpart by using a different delivery
vehicle or adjuvant system and whether the immunogenicity and
protective efficacy of nApa differs from rApa in FIA, the adjuvant
used for T cell hybridoma generation. However, immunization with
a mannosylated model peptide in Freund’s complete adjuvant
(FCA) has been previously shown to induce poor Th1 effector
functions despite enhanced Ag presentation [34]. Nonetheless, the
ability of rApa to impart protection in this study is consistent with
previous observation that i.n. subunit vaccination using rApa
protein imparts notable protection in mice [18].
Figure 7. Pathogen-specific responses in Apa vaccinated and control mice after challenge. (A) The proportions of STCF-specific 1+, 2+
and 3+ cytokine producers (of IFN-c, TNF-a and IL-2) constituting STCF-specific total cytokine positive (+) CD4+ or CD8+ T cells are plotted as % of
CD4+ T cells or CD8+ T cells in the lung and spleen of Apa vaccinated and control mice. Data are means 6 s.e.m. of 4 mice/group. (B) The frequency of
STCF-specific IFN-c, IL-17 or IL-4 SFU/106 pooled spleen or lung cells of vaccinated and control mice. Data are means 6 s.e.m. of 3 wells. The
corresponding pie charts present mean cytokine frequencies. *Significant by 1-way ANOVA followed by Bonferroni’s test comparing responses of
each vaccinated group with adjuvant control group post-challenge.
doi:10.1371/journal.ppat.1003705.g007
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Of note, a comparable protection was offered by nAg85B and
nApa vaccination despite the presence of 10 to 30-fold higher
magnitude of immunogen-specific lung CD8+ and CD4+ T cells in
nAg85B vaccinated mice (data not shown). In addition, WCL-
specific T cell responses induced by BCG in the lung prechallenge
were 2 to 5-fold lower than the immunogen-specific responses
induced by nAg85B vaccination, but, the protection imparted by
nAg85B was not better than BCG. These results suggest that no
direct correlation exists between the magnitude of immunogen-
specific T cell responses induced by subunit vaccination and the
degree of protection afforded against Mtb challenge. Previously we
have shown that the Mtb proteins selected on the basis of dominant
T cell and IFN-c response during human infection do not
necessarily impart stronger protection in vaccination experiments
[35–36]. Interestingly, the decreased T cell responsiveness with
higher dose (10 mg) Apa vaccination did not adversely affect the
protection using either form in challenge experiments. Under-
standing the mechanism of such immune regulation and Apa
vaccination induced protection will require further investigation.
One of the important findings in this study is the particularly
significant protective efficacy of Apa when used as a BCG-booster
vaccine against Mtb challenge in the elderly mice with waning
BCG induced protective immunity. Stronger and comparable
protection observed in the nApa or rApa-boosted BCG mice,
whose T cell responses are mainly primed against mannose
modifications of nApa, further suggests that mannosylation of Apa
is dispensable for BCG-boosting potential. It is conceivable that a
similar effect might be seen in humans previously vaccinated with
BCG in childhood and whose immunity has waned, although of
course, this would require clinical verification.
The progress of glycoproteins as vaccine candidates often suffers
a serious roadblock during the developmental pipeline. It is usually
due to perceived loss of immunogenicity when produced as a
recombinant protein, synthetic peptides or DNA vaccine due to
complete absence or lack of appropriate glycosylation. Despite
effectiveness of several glyco-conjugate vaccines against extracel-
lular pathogens, it has been suggested that artificial glycosylation
of peptides and targeting of CLRs may not always lead to
generation of protective immunity [37], as CLRs are also targeted
by pathogens to evade host immune responses [5,38]. Further-
more, some ligand-MR interactions can result in promotion of
Th2, anti-inflammatory or regulatory responses and may even
lead to T cell anergy and tolerance [34,39]. Glycosylation can
mask protective epitopes in Ag, prevent effective Ag processing,
inhibit proteolysis by masking cleavage sites and shift the pattern of
peptides processed by DCs [40,41]. Contrarily, tolerance induc-
tion or CLR engagement can be a disease defense strategy [42,43]
and it is argued that a mere ‘Th1 vaccine’ employing conserved
immunodominant Ags can induce hyper-immune activation and
may be advantageous to Mtb [44] and a complex balance between
pro- and anti-inflammatory host factors is required to prevent and
control Mtb infection [45]. Our results, therefore, underscore the
importance of conducting comparative protection studies in
animal models with a glycosylated Ag and its non-glycosylated
counterpart. This may prevent elimination of poorly antigenic but
otherwise protective non-glycosylated candidate during preclinical
evaluation and may help save lengthy, costly and complex
developmental efforts to artificially glycosylate it, carried out with
the aim to improve its immunogenicity.
In summary, we provide the evidence that the natural
glycosylation of a protein may differentially affect its antigenicity
and immunogenicity- the two attributes known to influence the
protective efficacy of TB subunit vaccines [19,46]. Although Apa
mannosylation influences T cell antigenicity during infection, it is
expendable for induction of protective immunity following
vaccination. Recently, a protein-O-mannosylating enzyme has
been found to be required for virulence of Mtb [47] and our results
highlight the need for further investigation of the role of increased
Figure 8. BCG booster potential of Apa. (A–D) Mice were vaccinated s.c. with 16106 CFU BCG and 16 months later boosted twice with either
saline alone or nApa or rApa (1 mg/dose) in DDA-MPL by same route. (A) Percentages (%) of nApa- or rApa-specific IFN-c producing cells among lung
or spleen CD4+ T cells of 3 groups of mice were determined 5 wks after last booster dose. Data are means 6 s.e.m. of 4 mice/group. (B) The frequency
of nApa- or rApa-specific IFN-c, IL-17 or IL-4 SFU/106 pooled lung or spleen cells are plotted. *Significant by 1-way ANOVA followed by Bonferroni’s
test comparing nApa-specific responses of saline booster group with those of Apa-boosted groups. (C) Protective efficacy of nApa, rApa or saline
boosted BCG mice against Mtb challenge was determined. The differences in bacterial load between BCG boosted and age-matched naı̈ve mice
(n = 5–6/group), 6 wks post-challenge are shown. (D) ESAT-6+CFP-10-specific IFN-c response in the spleens of mice was determined as a surrogate for
bacterial burden. Data are mean 6 s.e.m. of 4 mice/group for CD4+ T cell response (top) and mean 6 s.e.m. of triplicate cultures for total SFU
response (bottom). *Significant by Kruskal-Wallis test followed by Dunn’s test, ns- non-significant with respect to age matched naı̈ve controls.
doi:10.1371/journal.ppat.1003705.g008
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mannosylated epitope-specific T cells in infection. In view of the
finding that Mtb Apa improves waning BCG immunity and
imparts significant protection in elderly mice, it makes a strong




The study was approved by the Institutional Review Board of
Centers for Disease Control and Prevention (CDC), Atlanta,
Georgia, USA, (approved protocol number 1652), and informed
written consent was obtained from all human participants before
withdrawal of venous blood. All animal experiments performed in
BSL-II or BSL-III animal facilities were in strict accordance with
the guidelines of the U.S. Public Health Service Policy on the
Humane Care and Use of Animals and the Guide for the Humane
Care and Use of Laboratory Animals. The Institutional Animal
Care and Use Committees of Centers for Disease Control and
Prevention, Atlanta, Georgia, and the Colorado State University,
Fort Collins, Colorado, USA reviewed and approved these animal
protocols (approval numbers SABMOUC1664, 1847, SHIMOUC
1490 and CSU 98-026A).
Antigens
The nApa was purified from Mtb H37Rv culture filtrate by
traditional and reversed-phase chromatography as described
previously [8]. The recombinant clone for Apa (pMRLB.17),
WCL, STCF, nAg85B, rESAT-6 and rCFP-10 of Mtb H37Rv
were obtained through the NIH Biodefense and Emerging
Infection Research Resources Repository. The rApa was
expressed in E. coli BL21 (DE3) and purified from lysates by
Nickel chromatography with endotoxin removal using analo-
gous methods described elsewhere [48] followed by DEAE-
Sepharose chromatography. The overlapping peptides of Apa
and the C-terminal 45-mer and 49-mer (glyco) peptides were
synthesized by the Fmoc/tbu solid-phase peptide synthesis
strategy [49,50]. See Supplementary Methods (Text S1) for
details.
Human Subjects
Blood was obtained from 50 healthy adult individuals (26 BCG+
and 24 BCG2). All donors were HIV negative and were without
any clinical signs of TB. All BCG+ donors received BCG as a
neonatal vaccine. We excluded responses of 1 BCG2 and 2 BCG+
donors who tested positive for hepatitis. All 16 BCG+ donors with
positive tuberculin skin test reactivity (.10 mm induration after
intradermal injection) had normal chest radiographs. However, 1
BCG2 and 4/16 BCG+ donors demonstrated positive reactivity to
ESAT-6+CFP-10 in PBMC ELISPOT assay. The Mtb exposure of
these donors was further confirmed by commercial IFN-c
ELISPOT (Oxford Immunotech) and ELISA (Cellestis) tests
(IGRAs). Remaining 22 BCG2 donors had negative tuberculin
skin test and no known history of contact with individuals with TB.
The exposure of donors to environmental mycobacteria is not
known but all live in Atlanta area with very low incidence of
atypical mycobacterial infections. All donors demonstrated reac-
tivity to phytohaemagglutinin (PHA) in ELISPOT assay and none
were anergic.
Vaccinations and Experimental Infections of Mice
Specific-pathogen-free, 6–8 wk old female BALB/c (H-2d) mice
(Harlan Sprague Dawley) were used in the study. BCG vaccinated
mice received 100 ml of 16106 CFU Copenhagen s.c. above the
gluteus superficialis and biceps femoralis muscles of hind legs
(50 ml/leg). For protein vaccination, groups of mice received
200 ml of nApa, rApa or nAg85B (1 or 10 mg) in DDA and MPL
(from Salmonella minnesota Re 595) [51] s.c. on hind legs (100 ml/leg)
either 3-(subunit) or 2-times (prime-boost vaccination). Mtb
infections were performed i.n. with 56104 CFU Erdman strain.
At 48 h after Mtb challenge, about 0.5% of the total CFU
delivered could be cultured from the lungs. The bacterial burden
was determined by plating organ homogenates onto Middlebrook
7H10 agar supplemented with OADC and TCH (2 mg/ml). CFU
were enumerated after 4 wks of incubation at 37uC.
ELISPOT Assay
IFN-c, IL-4 or IL-17A ELISPOT assay was performed using
commercially available human or mouse ELISPOT reagent set
(BD-Biosciences) according to the manufacturer’s protocol as
described previously [18], except that no DCs were added as
supplemental APCs and cells were stimulated with 10 mg/ml of
purified or complex Mtb Ags, synthetic peptides or di-mannose
(unless mentioned otherwise) for 40 h in RPMI-1640. See
Supplementary Methods (Text S1) for details.
Flow Cytometry
Expression of cell surface markers and intracellular cytokine
production by human PBMCs or mouse organ cells after in vitro
stimulation with Mtb Ags (10 mg/ml) at 37uC for total 12 h was
assessed as described previously [52]. See Supplementary Methods
(Text S1) for details.
Binding/Uptake Assay
For fluorescent labeling of proteins, commercially available
FITC labeling kit (Pierce Biotechnology) was used. The protein
labeling was carried out in 50 mM sodium borate buffer (pH 8.5)
using 2 mg/ml protein concentration. Unreacted excess florescent
dye was removed using spin columns with purification resin as per
the manufactures instructions. Protein concentration was assessed
using the BCA assay (Sigma). The efficiency of labeling was
determined by Nano Drop Fluorospectrometer and was compa-
rable between nApa and rApa. Protein samples were stored in the
dark at 220uC before use. Human blood monocyte derived DCs
(MoDCs) were generated as described before [53] using recom-
binant human GM-CSF (80 ng/ml) and IL-4 (40 ng/ml) (Pepro-
Tech). Freshly isolated human PBMCs or MoDCs (day 6) were
pulsed with FITC-labeled nApa, rApa or WCL (20 mg/ml) and
incubated at 4uC or 37uC for the indicated amounts of time. Cells
were washed with PBS containing 10% FBS. Samples were then
stained with desired Abs to identify DC subsets and analyzed using
flow cytometry.
CLR Adhesion Assay
Mtb nApa or rApa was coated onto ELISA plates (Nunc,
Maxisorp) at 5 mg/well in 0.1 M carbonate-bicarbonate buffer
(pH 9.6); and coating took place for 18 h at room temperature.
Wells coated with 5 mg/well of purified BSA fraction-V (Fisher
Scientific) were used as negative controls while those coated with
Mtb H37Rv WCL or mannose caped LAM served as positive
controls. Blocking was carried out with 1% BSA for 30 min at
37uC and additional 1.5 h at room temperature in TSM buffer
(20 mM Tris-HCL (pH 7.4) containing 150 mM NaCl, 2 mM
CaCl2 and 1 mM MgCl2) [54]. Soluble recombinant human DC-
SIGN (CD209)-Fc chimera, DC-SIGNR (CD299)-Fc chimera or
MR (CD206) (R&D Systems) (2.5 mg/ml in TSM buffer) was
added and the adhesion was performed for 2 h at room
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temperature. Unbound CLR was washed away and the binding of
DC-SIGN-Fc or DC-SIGNR-Fc was determined by an anti-IgG1-
Fc ELISA using a peroxidase conjugate of goat anti-human-Fc.
Binding of MR was determined by anti-human-MR (CD206)
mouse mAb (clone 685641; R&D Systems) followed by peroxidase
conjugate of anti-mouse IgG. The plates were developed using o-
phenylenediamine dihydrochloride (Sigma-Aldrich) and absorp-
tion was measured at 492 nm. Specificity of CLR binding was
determined by blocking the interaction in the presence of either
2 mg/ml mannan or 5 mM EDTA (OD 492 nm ,0.1).
Ag Processing and Presentation Assay
The PBMCs were isolated from the venous blood of healthy
BCG+PPD+ human donors who responded to nApa in IFN-c
ELISPOT assay. Recombinant human GM-CSF and IL-4
developed MoDCs (day 6) were used as APCs while T cells
purified from the PBMCs of respective donors using ‘Dynabeads
Untouched Human T Cells’ purification kit (Invitrogen) and
magnetic separation (.95% pure) were used as effector cells.
APCs (26106) were pulsed with either nApa (10 mg/ml) or SEB
(1 mg/ml) or without any Ag (complete RPMI-1640 media only)
and incubated at 37uC. After 4 h, APCs were washed with RPMI-
1640 and were either left untreated or fixed with 0.05%
glutaraldehyde for 5 min at 22uC. APCs were washed and the
fixation was stopped by incubation with 0.2M glycine in RPMI-
1640 at 22uC. After 5 min, cells were washed 4 times with RPMI-
1640. Alternatively, APCs were fixed and Ag pulse was carried out
for 4 h. APCs were washed 4 times after Ag pulse and were co-
cultured with purified T cells (1:2 ratio) in ELISPOT plates pre-
coated with anti-human IFN-c capture Abs. After 40 hr of
incubation at 37uC in the presence of 5% CO2, ELISPOT plates
were developed and SFU were counted.
Generation of nApa-Specific T Cell Hybridomas and IL-2
Assay
T-cell hybridomas specific for Mtb nApa were generated as
previously described [55]. Briefly, four BALB/c mice were each
vaccinated with 40 mg of nApa in FIA by injecting 25 ml into each
hind footpad and the remainder at the base of the tail. Five days
after the vaccination, the draining lymph nodes (popliteal, inguinal
and periaortic) were harvested to obtain lymph node (LN) cells.
The primed LN cells were restimulated in vitro with syngeneic bone
marrow derived dendritic cells (BMDCs) that had been pulsed
with 10 mg/ml nApa per well. Approximately 16106 primed LN
cells were added per well in two 24-well tissue culture plates in a
total volume of 1 ml of complete RPMI 1640 medium (RPMI
1640 supplemented with 10% FCS, 561025M 2-ME (Sigma), plus
a nutrient cocktail as described [56]). After two days of culture, the
cells were harvested and pooled from all 48 wells, washed, fused
with the T cell fusion partner BWa2b2 [57], and plated out into
ten 96-well plates. Clones that grew in individual wells were
screened using either BMDCs, as above, or a BALB/c mouse-
derived B cell lymphoma line, A20 [58], pulsed with 0.5 mg/well
nApa. The selection of responding T cell hybridomas was
performed by assaying 24 hr culture supernatants using paired
rat monoclonal Abs specific for mouse IL-2 (Pharmingen/BD-
Biosciences) in a capture ELISA. For Ag presentation studies,
microculture wells were prepared containing 250 ml of culture
medium, 56104 each of T cell hybridoma and APC, and a known
amount of nApa or rApa (intact or trypsin digested), in
flat-bottomed 96-well microtiter wells. Dose response curves with
native and recombinant Ags were performed to determine which
T cell hybridomas responded nApa alone, or to both the native
and recombinant form of the protein. T cell hybridomas were
further tested with a panel of synthetic, overlapping, nonglycosy-
lated Apa peptides or trypsin digested and RP-HPLC separated
nApa fractions to determine the peptide epitopes that were
recognized. For details regarding trypsin digestion of Apa and
characterization of RP-HPLC fractions please refer to Supple-
mentary Methods (Text S1).
Ab ELISA
ELISA assays of mouse sera were performed as described
previously [46], using 2 mg/ml of nApa or rApa for coating and
HRP-conjugated anti-mouse IgG1, IgG2a (BD-Pharmingen) and
IgG2b (Santa Cruz Biotech) Abs for detection.
Statistical Analyses
Differences between groups were assessed by the parametric
Student’s t test or 1-way ANOVA followed by Bonferroni’s test
and the nonparametric 2-tailed Mann-Whitney U-test (the
Wilcoxon test for matched pairs) or Kruskal-Wallis followed by
the Dunn’s post-test (GraphPad Prism program). Unless indicated,
all immune response data are presented after subtracting no Ag
control values. A value of p,0.05 was considered to be significant
and * ,0.05; ** ,0.01; *** ,0.001.
Accession/Identification Numbers
The accession/identification numbers of Mtb proteins used in
the study are Mtb (H37Rv) alanine and proline-rich antigen (Apa),
Rv1860, NCBI reference sequence: YP_177849.1; Mtb (H37Rv)
Ag85B, Rv1886c, NCBI reference sequence: NP_216402.1; Mtb
(H37Rv) 6 kDa early secretory antigenic target (ESAT-6),
Rv3875, NCBI reference sequence: YP_178023.1; Mtb (H37Rv)
10 kDa culture filtrate protein (CFP-10), Rv3874, UniProtKB/
Swiss-Prot reference sequence: P0A566.2.
Supporting Information
Figure S1 Human PBMC responses to nApa and rApa.
(A) IFN-c response kinetics of purified nApa and rApa in the
PBMCs of healthy PPD+ donors with (+) or without (2) BCG
vaccination and ESAT-6 and CFP-10 reactivity, following in vitro
stimulation with increasing amounts of Ag (0.1 to 10 mg/ml) in
ELISPOT assay. Each symbol represents an individual donor,
while the horizontal bar indicates a median response. (B) Cytokine
expression profiles of nApa and rApa- specific CD4+ T cells.
PBMCs from PPD+ (n = 8) or PPD2 (n = 3) BCG vaccinated
donors were stimulated with nApa, rApa or WCL (10 mg/ml) and
IFN-c, IL-2 and TNF-a cytokine co-expression profiles were
determined using the Boolean gating. The proportions of subsets
of CD4+ T cells positive for one (1+), any combination of two (2+),
or all three (3+) cytokines constituting total cytokine positive (+)
Ag-specific CD4+ T cells were determined for each donor and
expressed as percentages of CD4+ T cells and plotted as
histograms. The pie charts present the mean frequencies of single
(1+), double (2+) and triple (3+) cytokine producers of BCG+PPD+
donors specific for each Ag. (C–D) Uptake of nApa and rApa by
DCs. The PBMCs from the healthy BCG+PPD+ or BCG2PPD2
individuals or MoDCs from the BCG+PPD+ individuals (n = 3)
were pulsed with indicated FITC-labeled Ags for 2 h and Ag
uptake was analyzed by flow cytometry. (C) A histogram gated on
CD11c+HLA-DR+ cells is shown from one representative
experiment using PBMCs from BCG+PPD+ individual and pulsed
with FITC-nApa (dark blue histogram) and FITC-rApa (light blue
histogram) for 2 h at 37uC. Background uptake of nApa-FITC
after 2 h at 4uC is shown (white histogram). (D) Summary of
FITC-labeled nApa and rApa uptake by CD11c+HLA-DR+ blood
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DCs and MoDCs in vitro. The MFI is represented by the geometric
mean of the gated CD11c+HLA-DR+ peak. The data are means 6
s.e.m. of three independent experiments. *Significant using 1-way
ANOVA followed by Bonferroni’s test. (E) Processing and
presentation of nApa to T cells. APCs (MoDCs) from nApa
responding BCG+PPD+ individuals (n = 3) were fixed with
glutaraldehyde before or after pulsing with no Ag, nApa or SEB
for 4 h at 37uC. A set of APCs were also pulsed without fixing for
4 h. After incubation APCs were washed and cultured with T cells
purified from the PBMCs of the respective individuals for 40 h in
IFN-c ELISPOT plates. The data are mean 6 s.e.m SFU/106
purified T cell from 3 individuals evaluated in duplicate cultures.
TNTC- too numeric to count. (F) Synthetic peptide screenings.
The frequency of nApa, rApa or 32 individual non-modified
synthetic Apa peptides-specific IFN-c secreting cells in the PBMCs
of BCG+PPD+ donors recognizing both nApa and rApa or those
recognizing nApa much better than rApa was determined by
ELISPOT assay and expressed as mean SFU/106 PBMCs.
(TIF)
Figure S2 nApa is more antigenic than rApa in BCG and
Mtb infected mice. (A–C) Mice were infected s.c. with
16106 CFU BCG, or (D–F) i.n. with 56104 CFU Mtb. At
different time points after infection, as indicated, mice were
euthanized and their spleen or lung cells were stimulated in vitro
with no Ag, nApa, rApa, nAg85B or WCL. (A) The percentages
(%) of TNF-a and IFN-c (top) or IL-2 (bottom) producing cells
among spleen CD4+ T cells from one representative experiment at
the 52 wk time point are shown, and (B) the frequency (%) of
nApa- or rApa-specific IFN-c, IL-2 or TNF-a producing cells
among CD4+ and (C) IFN-c producing cells among CD8+ T cells
from the spleen and lung at 7 different time points are plotted.
Data at 12, 32, 52 and 72 wks (in B–C) are means 6 s.e.m. of 3–4
independent mice experiments, while data (means) at 3, 6 and
104 wks are from one experiment using pooled cells (n = 4 mice)
evaluated in duplicate. (D–F) T cell response in Mtb infected mice.
(D) nApa- or rApa-specific IFN-c, IL-2 and TNF-a cytokine co-
expression profiles in the spleen and lung were determined at 12
and 26 wks after infection and the proportions of single (1+),
double (2+), or triple (3+) cytokine producing T cell subsets
constituting total cytokine positive (+) CD4+ or CD8+ T cells are
plotted as % of CD4+ T cells (right) or CD8+ T cells (left),
respectively. Total as well as individual subset responses are
compared. (E) The percentages of 7 possible combinations of
cytokine secreting CD4+ or CD8+ T cell subsets in the lung at
26 wks are also plotted. Data at 12 wks are means 6 s.e.m. of
pooled cell culture in triplicate while at 26 wks are of individual
mice (n = 4). (F) nApa or rApa-specific IFN-c, IL-17 or IL-4 SFU/
106 spleen or lung cells at 26 wks. Data are means 6 s.e.m. of
triplicate or quadruplet cultures. * Significant using 1-way analysis
of variance (ANOVA) followed by Bonferroni’s multiple compar-
isons test (B–F).
(TIF)
Figure S3 Amino acid sequence of Mtb Apa and
synthetic C-terminal glycopeptides and antigenicity. (A)
Structure of a synthetic 45-mer C-terminal Apa glycopeptide
(residues 281–325). (B) Amino acid sequence of Apa. The signal
peptide and the sequence of the protein are indicated in italic
and bold-faced type, respectively. Parentheses indicate amino
acid 137, phenylalanine for Mtb, and leucine for BCG. The
sequence of synthetic 45-mer C-terminal glycopeptide and control
non-glycopeptide (residues 281–325) evaluated in this study is
indicated in the box. Threonine (Thr) residues at positions
50 and 57 are naturally glycosylated with mannobiose
(a-D-Manp(1R2)a-D-Manp), the Thr residue at position 66 is
modified with a single mannose (a-D-Manp), and Thr-316 is
glycosylated with either a mannose, a mannobiose, or a
mannotriose (a-D-Manp(1R2)a-D-Manp(1R2)a-D-Manp) (indi-
cated in red color). The T cell epitope prediction analysis using
IEDB program (http://www.immuneepitope.org/) indicated the
probable binding of a 15-mer (residues 309–323) encompassing
Thr316 to MHC class-II molecules encoded by H2I-Ad and H2E-
Ad alleles, while peptide p271-288 is predicted to consist of 2
overlapping 9-mers with high affinity for MHC class-I molecules
encoded by H2Kd allele (IEDB and http://www.syfpeithi.de/).
The black solid line, dotted line and blue line indicates IEDB
program predicted CD8+, CD4+ and B-cell epitopes (based on
Kolaskar and Tongaonkar antigenicity) in Apa C-terminal domain
(residues 271–325), respectively. (C) Structure of a synthetic 49-
mer glycopeptide comprised of Apa peptide (residues 281–325,
non-glycosylated at Thr-316) and N-terminal extension bearing
dimannosyl-Thr residue linked to Apa 45-mer sequence via Gly-
Gly dipeptide unit. (D) Synthetic 45-mer glycopeptide-, 49-mer
glycopeptide- and free di-mannose-specific cytokine responses of
BCG infected mice in ELISPOT assay. Stimulation with mature
proteins (nApa or rApa) or non-glycopeptides (45-mer and 49-mer)
was included as controls. Ag- or peptide-specific IFN-c, IL-17 or
IL-4 SFU/106 pooled lung, spleen or ILN cells of BCG infected
mice at 58 weeks are shown. Data are means 6 s.d. *Significant
using 1-way ANOVA followed by Bonferroni’s test.
(TIF)
Figure S4 Immunogenicity of nApa and rApa in mice.
(A) Mice were vaccinated with nApa or rApa (1 mg/dose) in DDA-
MPL adjuvant and 1 wk after last vaccination their ILN cells
(pools of 4 mice/group) were stimulated in vitro with nApa or rApa.
The frequency (%) of nApa- or rApa-specific TNF-a, IL-2 or IFN-
c cytokine producing cells among CD4+ T cells is plotted. (B)
Synthetic peptide screenings. The frequency of nApa-, rApa- or 32
individual non-modified synthetic Apa peptides-specific IFN-c, IL-
17 or IL-4 cytokine secreting cells in the spleen of 10 mg/dose
nApa or rApa vaccinated mice was determined 1 wk after last dose
using ELISPOT assay and expressed as mean SFU/106 cells 6
S.D. Similar peptide recognition pattern was observed after 1 mg/
dose vaccination.
(TIF)
Figure S5 Fractionation of nApa trypsin-digest and LC-
MS analysis of fractions. (A) The RP-HPLC fractionation of
nApa trypsin-digest. A chromatogram with relative abundance of
each fraction is shown. (B) LC-MS analysis of nApa trypsin-digest.
A portion of each fraction was analyzed by LC-MS to identify the
peptides represented by each fraction. Fraction 19 (shown), 21,
and 22 (not shown) demonstrated the presence of the N-terminal
glycopeptide for nApa, mannosylated with 5 (predominant) 4, or 3
residues. No other significant products were found in the most
active fractions (19 and 22). The amino acid sequence of the N-
terminal nApa glycopeptide is shown in the box.
(TIF)
Figure S6 Both nApa and rApa are recognized equally
well in Apa vaccinated and challenged mice. (A–B) Mice
were vaccinated with nApa or rApa (either 1 or 10 mg/dose) in
DDA-MPL adjuvant. Four wks after last vaccination dose, mice
were challenged with Mtb as described in Figure 5. T and B cell
responses to both nApa and rApa were investigated at the time of
challenge and 6 wks post-challenge. (A) The frequency (%) of
TNF-a, IL-2 or IFN-c cytokine producing cells in the lung and
spleen cells of Apa (1 mg/dose) vaccinated and challenged mice
after in vitro stimulation with nApa or rApa are shown. Data are
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average response of 4 mice/group (6 s.e.m.). (B) Anti-nApa and
anti-rApa IgG1, IgG2a and IgG2b antibody titers in the sera of
Apa vaccinated mice before and after challenge. Data are average
response of 4 mice/group (6 s.e.m.).
(TIF)
Text S1 Supplementary information. Supplemental infor-
mation includes details of peptide synthesis, ELISPOT assay, flow
cytometry, trypsin proteolysis of Apa and RP-HPLC fractionation
of digests, and Table S1.
(DOCX)
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